欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
ERK-IN-1_1715025-32-3_产品详情
1715025-32-3
  • names:

    ERK-IN-1

  • CAS号:

    1715025-32-3

    MDL Number:
  • MF(分子式): C26H27BrF3N5O2 MW(分子量): 578.42
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
ERK-IN-1
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名 ERK-IN-1
CAS号 1715025-32-3
Inchi
InchiKey
分子式 Formula C26H27BrF3N5O2
分子量 Molecular Weight 578.42
溶解度Solubility
性状
储藏条件 Storage conditions 请根据产品建议的存储条件进行存储,Please store the product under the recommended condition sin the description.
产品说明
IntroductionERK-IN-1 (compound B) is aRAFandERK1/2inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC (non-small celllung cancer), BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovanan cancer[1].
Application1
Application2
Application3
ERK-IN-1 (compound B) 为RAF和ERK1/2的抑制剂,通过激活MAPK通路中的突变来治疗增生性疾病。这种活性与KRAS-突变型非小细胞肺癌、BRAF-突变型非小细胞肺癌、KRAS-突变型胰腺癌、KRAS-突变型结肠癌以及KRAS-突变型卵巢癌尤为相关。ERK-IN-1 (compound B) is aRAFandERK1/2inhibitor in the treatment of a proliferative disease characterized by activating mutations in the MAPK pathway. The activity is particularly related to the treatment of KRAS-mutant NSCLC (non-small celllung cancer), BRAF-mutant NSCLC, KRAS-mutant pancreatic cancer, KRAS-mutant colorectal cancer (CRC) and KRAS-mutant ovanan cancer[1].
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.WO2018051306A1.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents